Neurology and Neurosurgery

Guest: Jonathan Strober, MD Misinterpreted symptoms and limited access to treatment can make it difficult to manage myasthenia gravis among adolescents and young adults. Join Dr. Jonathan Strober as he explains how we can address gaps in care for this population. Dr. Strober is a Professor of Neurology at the University of California, San Francisco and the Director of the Neuromuscular Clinic at UCSF Benihoff Children’s Hospital.

Guest: Gil I. Wolfe MD, FAAN Rozanolixizumab is a fast-acting myasthenia gravis treatment that reduces IgG levels by blocking the neonatal Fc receptor. Dr. Gil Wolfe explains how it compares to other treatment options like corticosteroids, taking side effects and quality of life into consideration. Dr. Wolf is a SUNY Distinguished Professor of Neurology at the University of Buffalo Jacobs School of Medicine and Biomedical Sciences.

Guest: Henry Kaminski, MD Generalized myasthenia gravis (gMG) is a complex autoimmune disease with a wide range of symptoms, from ocular issues to severe muscle weakness. As our understanding of the pathophysiology behind gMG evolves, so does our ability to improve patient management. Join Dr. Henry Kaminski as he examines emerging advancements in gMG treatment, including FcRN inhibitors and immune-targeting therapies. Dr. Kaminski is the Meta A. Neumann Professor of Neurology at the George Washington University School of Medicine and Health Sciences.

Guest: Nicholas J. Silvestri, MD, FAAN FcRn inhibitors provide a targeted approach to generalized myasthenia gravis (gMG) treatment by reducing pathogenic antibodies. These therapies offer fewer side effects compared to traditional treatments like corticosteroids, improving both disease control and quality of life. Dr. Nick Silvestri, a Professor of Neurology at the University of Buffalo Jacobs School of Medicine and Biomedical Sciences, explains this treatment’s potential.

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.

Host: Jacob Sands, MD Guest: Aaron Lisberg, MD Unfortunately, brain metastases are very common in patients with non-small cell lung cancer (NSCLC). That’s why the phase 3 TROPION-Lung01 trial examined the efficacy and safety of datopotamab deruxtecan (Dato-DXd) for advanced non-squamous NSCLC with brain metastases. Joining Dr. Jacob Sands to share the results presented at the 2024 ESMO Congress is thoracic medical oncologist Dr. Aaron Lisberg.

Host: John Russell, MD Guest: Noel Dasgupta, MD, FACC Guest: Sami Khella, MD Amyloidosis, often unrecognized, misdiagnosed, and either inappropriately treated or undertreated, is a collection of diseases caused by the misfolding of proteins that aggregate into insoluble amyloid fibrils and deposit in tissues. There are two prominent forms of amyloidosis misfolding of light chain proteins (AL amyloidosis) and transthyretin protein misfolding (ATTR amyloidosis). In this program, two experts in amyloidosis, cardiologist Dr. Noel Dasgupta and neurologist Dr. Sami Khella, will explain the pathophysiology of amyloidosis, describe the prognosis for patients, discuss timely patient screening and diagnostic testing, and provide updated treatment options.

Host: Jennifer Caudle, DO Guest: Lori Guyton, MD Guest: Douglas Scharre, MD As our understanding of Alzheimer’s disease continues to evolve, it’s critical to understand the clinical and pathologic changes underpinning Alzheimer’s disease as it may be able to help guide early diagnosis and clinically meaningful management decisions. That’s why Drs. Douglas Scharre and Lori Guyton speak with Dr. Jennifer Caudle about Alzheimer’s disease pathophysiology and how it translates to clinical practice. Dr. Scharre is a Professor of Clinical Neurology and Psychiatry as well as the Director for the Division of Cognitive Neurology at the Ohio State University Wexner Medical Center in Columbus, and Dr. Guyton is a practicing neurologist with Neurology of Southern Illinois in Herrin. Reference: J Prev Alzheimers Dis © Eisai Inc. 2024. All Rights Reserved. AD-M2130 November 2024

Host: Jennifer Caudle, DO Guest: Lori Guyton, MD Guest: Douglas Scharre, MD Our understanding of the mechanisms underlying Alzheimer’s disease is growing, and these advances can help inform diagnosis and management strategies. In fact, as our understanding of Alzheimer’s disease evolves, our strategies to diagnose and manage the disease are changing to focus on early diagnosis and intervention. Joining Dr. Jennifer Caudle to discuss our current understanding of disease progression as well as the impact and benefit of diagnosing Alzheimer’s disease early are Drs. Douglas Scharre and Lori Guyton. Dr. Scharre is the Director of the Division of Cognitive Neurology at the Ohio State University Wexner Medical Center in Columbus, and Dr. Guyton is a practicing neurologist with Neurology of Southern Illinois in Herrin. Reference: Med Clin North Am © Eisai Inc. 2024. All Rights Reserved. AD-M2123 November 2024

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Douglas Drossman, MD While neuromodulators are primarily used to treat psychiatric disorders, they can also help normalize symptoms of irritable bowel syndrome by targeting the gut-brain axis. In fact, about half of all patients with IBS have the potential to benefit from neuromodulators. Dr. Douglass Drossman joins Dr. Peter Buch to discuss his research on how various neuromodulators can provide relief for IBS patients. Dr. Drossman is the President of the Drossman Center of Education and Practice of Psychosocial Care and Drossman Consulting as well as a Professor Emeritus of Medicine and Psychiatry at the University of North Carolina School of Medicine.

Guest: Kelly Gwathmey, MD ALS can take up to a year to diagnose, but researchers are hard at work trying to find ways to minimize diagnostic delays and errors. One such solution is the Rapid Access ALS Clinic, where patients were diagnosed an average of two months sooner. Here to talk about this work is Dr. Kelly Gwathmey, Professor of Neurology at the Virginia Commonwealth University School of Medicine who presented a session on this topic at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting.